Financial Report: Teva

4Q Revenues: $6.5 billion (+33%)

4Q Loss: $974 million (earnings were $498 million 4Q15)

FY Revenues: $21.9 billion (+11%)

FY Earnings: $311 million (earnings were $1.6 billion YTD15)

Comments: Generic medicines revenues in the quarter were $3.7 billion, up 44%, reflecting the results of the Actavis Generics business from August 2, 2016. Specialty medicines revenues in the quarter were $2.2 billion, up 4% and comprised 34% of total revenues in the quarter, compared to 43% in 4Q15. Copaxone revenues were $1.0 billion, up 6%. Azilect revenues were $88 million, up 10%. ProAir revenues in the quarter were $139 million, down 6%, due to lower volumes related to changes in market access. QVAR global revenues were $116 million in the quarter, down 3%, mainly due to net pricing effects. Revenues of Treanda and Bendeka were $150 million, down 24%, due to increased competition from other therapies. Results reflect the Actavis Generics acquisition.